Norac Pharma

What Norac Pharma does

Norac Pharma is a privately held, family- and employee-owned API contract development and manufacturing organization (CDMO) headquartered in Azusa, California. Founded in 1970, the company operates from a single site offering an integrated service portfolio spanning Process R&D, preclinical API supply, Kilo Lab and Pilot Plant scale-up, multi-ton cGMP API manufacturing, analytical method development and validation, and Quality & Regulatory affairs. Technical capabilities include SafeBridge Category 3 high-potency compound handling, DEA licensure for Schedule 1-3 controlled substances, FDA-registered cGMP compliance (21 CFR 210/211 and ICH Q7A), and advanced analytical instrumentation including 400 MHz NMR, LC-MS/GC-MS, FTIR ReactIR, and Lasentec FBRM crystallization monitoring. Capacity scales from laboratory (50-100 g) through Kilo Lab (0.5-5 kg) to Pilot Plant (tens to hundreds of kilograms), with glass-line reactors up to 200 gallons and a temperature range of -50°C to 170°C.

The company serves US pharmaceutical clients across a horizontal segmentation that runs from small virtual biotechs requiring preclinical and early-clinical API supply to larger biopharmaceutical companies needing commercial-scale manufacturing, controlled-substance production, and potent-compound handling. GTM motion is enterprise field sales with direct engagement emphasizing close partnership, transparent communication, and seamless project transitions across development stages. Pricing is project-based with bespoke quotes rather than published rate cards.

Commercial mechanics are entirely project-driven: revenue is generated through one-time contract fees for process R&D, analytical services, and manufacturing engagements. Norac Pharma has no disclosed external funding, no parent company, no subsidiaries, no M&A history, and operates exclusively within the United States. Its competitive positioning rests on regulatory credentials, long-tenured process chemistry talent, and 50+ years of operating track record rather than on data, AI, or platform-economics advantages.

Name

Norac Pharma

Legal name

Norac Pharma

Website

https://noracpharma.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

51–100 employees

Short description

Norac Pharma is a privately held, FDA- and DEA-registered API CDMO in Azusa, California, offering cGMP process R&D, scale-up, and multi-ton API manufacturing — including high-potency and controlled substances — to US biotech and biopharma clients across preclinical through commercial stages.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• API contract manufacturing
• Pharmaceutical process R&D
• CGMP API production
• Analytical method development
• Controlled substance manufacturing

Headquarters

HQ city

Azusa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain

Revenue model

1. API Contract Manufacturing: Contract development and manufacturing services for Active Pharmaceutical Ingredients spanning preclinical through commercial phases. Revenue generated through project-based fees for process R&D, analytical services, and manufacturing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Norac Pharma is a single-site API contract development and manufacturing organization (CDMO) providing process research and development (PRD), analytical services, and cGMP manufacture of Active Pharmaceutical Ingredients and intermediates. Capabilities span laboratory scale (50g-100g) through Kilo Lab (0.5kg-5kg) to Pilot Plant scale (10s-100s kg), with specialized handling of high-potency compounds (SafeBridge Category 3) and DEA-licensed controlled substances. Services cover the full lifecycle from preclinical through commercial supply for pharmaceutical clients.

Product overview

Norac Pharma is a single-site API contract development and manufacturing organization (CDMO) offering an integrated portfolio of pharmaceutical services centered on Active Pharmaceutical Ingredient (API) process R&D and manufacturing. The core product suite consists of five interconnected service modules: API R&D (process discovery, research, and optimization), API Manufacturing (large-scale cGMP production), Preclinical (preclinical-scale supply), Analytical R&D (method development, validation, and testing), and Quality & Regulatory (compliance and regulatory affairs). These services are supported by dedicated facilities including Research labs, Kilo Lab, Pilot Plant, and Analytical facilities. The company specializes in high potency compounds (SafeBridge Category 3), controlled substances (DEA licensed for Schedule 1, 2, and 3), and offers scale-up from laboratory scale (50g-100g) through Kilo Lab (0.5kg-5kg) to Pilot Plant (10s-100s kg). The services are delivered as a unified offering where projects seamlessly transition between stages (discovery through preclinical, clinical trials, process validation, and commercialization) under one organizational structure.

Differentiator

Problem solved

Functional benefit

Products and services

• API R&D

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators4 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Albany Molecular Research (AMRI): AMRI is a contract research and manufacturing organization providing small-molecule API development, analytical services, and cGMP manufacturing across discovery, development, and commercial phases — directly comparable to Norac's integrated service model. Norac's President Peter Leeming previously held a senior role there, underscoring operational similarity.
• Cambrex Corporation: Cambrex is a small-molecule API CDMO offering process R&D, scale-up, and cGMP manufacturing from lab to commercial scale — closely overlapping Norac's core offering of API R&D, Kilo Lab, and Pilot Plant services with FDA-inspected facilities.
• Siegfried Holding: Siegfried is a Swiss-based API CDMO specializing in small-molecule process development and manufacturing, including controlled substances and HPAPI handling. Its multi-site model differs in scale but the service overlap with Norac's small-molecule API CDMO positioning is direct.
• Johnson Matthey Fine Chemicals: Johnson Matthey's Fine Chemicals division provides API custom development and manufacturing services including controlled substances and complex chemistry — directly comparable to Norac's DEA-licensed API manufacturing and process R&D offerings.
• Noramco: Noramco is an API manufacturer specializing in controlled substances and Schedule II/III narcotics at cGMP facilities, directly mirroring Norac's DEA-licensed capabilities for controlled-substance API manufacturing.

Broad incumbents

• Piramal Pharma Solutions: Piramal Pharma Solutions is a global CDMO offering API development and manufacturing across small molecules with multiple FDA-inspected sites. Its HPAPI capabilities and integrated service range place it as a broader incumbent competing for the same client base as Norac.
• Catalent: Catalent is a large global CDMO offering drug substance and drug product development across small molecules and biologics. While much broader in scope, it competes for outsourced API supply contracts in the same customer segment Norac serves.
• Lonza: Lonza is the world's largest CDMO offering comprehensive small-molecule and biologics API manufacturing. It competes with Norac on larger-scale commercial API supply, though Lonza's scale and global footprint far exceed Norac's single-site operation.
• Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher's pharma services business, offers API development and commercial manufacturing as part of a broader drug development and commercialization suite — competing with Norac on integrated small-molecule API programs.
• WuXi STA (WuXi AppTec): WuXi STA is a leading global API CDMO with extensive small-molecule process R&D and manufacturing capacity. As a much larger competing platform, it pressures Norac on price and scale for outsourced API development programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/norac

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Norac Pharma